Cardioprotective effects of amiodarone in a rat model of epilepsy-induced cardiac dysfunction.
Adjuvants, Immunologic
/ administration & dosage
Amiodarone
/ therapeutic use
Animals
Anti-Arrhythmia Agents
/ therapeutic use
Biomarkers
/ blood
Epilepsy
/ chemically induced
Glutathione
/ blood
Heart Diseases
/ drug therapy
Interleukin-1
/ metabolism
Lithium Chloride
/ administration & dosage
Male
Malondialdehyde
/ blood
Muscarinic Agonists
/ administration & dosage
Myocardial Contraction
/ drug effects
Pilocarpine
/ administration & dosage
Rats
Rats, Wistar
Superoxide Dismutase
/ blood
Troponin I
/ blood
amiodarone
anticonvulsant
electrocardiography
epilepsy
myocardial performance
oxidation
Journal
Clinical and experimental pharmacology & physiology
ISSN: 1440-1681
Titre abrégé: Clin Exp Pharmacol Physiol
Pays: Australia
ID NLM: 0425076
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
revised:
08
11
2021
received:
21
03
2021
accepted:
12
11
2021
pubmed:
20
11
2021
medline:
26
3
2022
entrez:
19
11
2021
Statut:
ppublish
Résumé
Cardiac dysfunction is one of the leading causes of death in epilepsy. The anti-arrhythmic drug, amiodarone, is under investigation for its therapeutic effects in epilepsy. We aimed to evaluate the possible effects of amiodarone on cardiac injury during status epilepticus, as it can cause prolongation of the QT interval. Five rat groups were enrolled in the study; three control groups (1) Control, (2) Control-lithium and (3) Control-Amio, treated with 150 mg/kg/intraperitoneal amiodarone, (4) Epilepsy model, induced by sequential lithium/pilocarpine administration, and (5) the epilepsy-Amio group. The model group expressed a typical clinical picture of epileptiform activity confirmed by the augmented electroencephalogram alpha and beta spikes. The anticonvulsive effect of amiodarone was prominent, it diminished (p < 0.001) the severity of seizures and hence, deaths and reduced serum noradrenaline levels. In the model group, the electrocardiogram findings revealed tachycardia, prolongation of the corrected QT (QTc) interval, depressed ST segments and increased myocardial oxidative stress. The in-vitro myocardial performance (contraction force and - (df/dt)
Identifiants
pubmed: 34796981
doi: 10.1111/1440-1681.13615
doi:
Substances chimiques
Adjuvants, Immunologic
0
Anti-Arrhythmia Agents
0
Biomarkers
0
Interleukin-1
0
Muscarinic Agonists
0
Troponin I
0
Pilocarpine
01MI4Q9DI3
Malondialdehyde
4Y8F71G49Q
Superoxide Dismutase
EC 1.15.1.1
Lithium Chloride
G4962QA067
Glutathione
GAN16C9B8O
Amiodarone
N3RQ532IUT
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
406-418Subventions
Organisme : Cairo University
ID : CU#721
Informations de copyright
© 2021 John Wiley & Sons Australia, Ltd.
Références
Beghi E. The epidemiology of epilepsy. Neuroepidemiology. 2020;54(Suppl. 2):185-191.
Fiest KM, Sauro KM, Wiebe S, et al. Prevalence and incidence of epilepsy. Neurology. 2017;88(3):296-303. 10.1212/WNL.0000000000003509
Smithson WH, Colwell B, Hanna J. Sudden unexpected death in epilepsy: addressing the challenges. Curr Neurol Neurosci Rep. 2014;14(12):502. Available from: http://link.springer.com/ 10.1007/s11910-014-0502-4
Donner EJ. Explaining the unexplained; expecting the unexpected: where are we with sudden unexpected death in epilepsy? Epilepsy Curr. 2011;11(2):45-49. 10.5698/1535-7511-11.2.45
Velagapudi P, Turagam M, Laurence T, Kocheril A. Cardiac arrhythmias and sudden unexpected death in epilepsy (SUDEP). Pacing Clin Electrophysiol. 2012;35(3):363-370. 10.1111/j.1540-8159.2011.03276.x
Ravindran K, Powell KL, Todaro M, O’Brien TJ, O’Brien TJ. The pathophysiology of cardiac dysfunction in epilepsy. Epilepsy Res. 2016;127(4):19-29. Available from https://linkinghub.elsevier.com/retrieve/pii/S0920121116301279
de Bruyne MC, Hoes AW, Kors JA, Hofman A, van Bemmel JH, Grobbee DE. QTc Dispersion Predicts Cardiac Mortality in the Elderly. Circulation. 1998;97(5):467-472. http://doi.org/10.1161/01.cir.97.5.467
Doggrell SA. Amiodarone - waxed and waned and waxed again. Expert Opin Pharmacother. 2001;2(11):1877-1890. 10.1517/14656566.2.11.1877
Kodama I. Cellular electropharmacology of amiodarone. Cardiovasc Res. 1997;35(1):13-29. 10.1016/S0008-6363(97)00114-4
Samarendra P, Kumari S, Evans SJ, Sacchi TJ, Navarro V. QT prolongation associated with azithromycin/amiodarone combination. Pacing Clin Electrophysiol. 2001;24(10):1572-1574. 10.1046/j.1460-9592.2001.01572.x
Kotoda M, Ishiyama T, Mitsui K, Hishiyama S, Matsukawa T. Neuroprotective effects of amiodarone in a mouse model of ischemic stroke. BMC Anesthesiol. 2017;17(1):168. 10.1186/s12871-017-0459-3
Banach M, Rudkowska M, Sumara A, Borowicz-Reutt K. Amiodarone enhances anticonvulsive effect of oxcarbazepine and pregabalin in the mouse maximal electroshock model. Int J Mol Sci. 2021;22(3):1041. Available from: https://www.mdpi.com/1422-0067/22/3/1041
Chang CY, Hung CF, Huang SK, Kuo JR, Wang SJ. Amiodarone reduces depolarization-evoked glutamate release from hippocampual synaptosomes. J Pharmacol Sci. 2017;133(3):168-175. Available from https://linkinghub.elsevier.com/retrieve/pii/S1347861317300385
Turovaya AY, Galenko-Yaroshevskii PA, Kade AK, et al. Effects of verapamil and amiodarone on sympathoadrenal system and balance of excitatory and inhibitory amino acids in rat medulla oblongata. Bull Exp Biol Med. 2005;139(6):665-667. 10.1007/s10517-005-0372-5
Banach M, Popławska M, Borowicz-Reutt KK. Amiodarone, a multi-channel blocker, enhances anticonvulsive effect of carbamazepine in the mouse maximal electroshock model. Epilepsy Res. 2018;140:105-110. Available from https://linkinghub.elsevier.com/retrieve/pii/S0920121117304588
André V, Dubé C, François J, et al. Pathogenesis and pharmacology of epilepsy in the lithium-pilocarpine model. Epilepsia. 2007;48(s5):41-47. 10.1111/j.1528-1167.2007.01288.x
Lüttjohann A, Fabene PF, van Luijtelaar G. A revised Racine’s scale for PTZ-induced seizures in rats. Physiol Behav. 2009;98(5):579-586. Available from https://linkinghub.elsevier.com/retrieve/pii/S0031938409003047
Koçer S, Canal MR. Classifying epilepsy diseases using artificial neural networks and genetic algorithm. J Med Syst. 2011;35(4):489-498. 10.1007/s10916-009-9385-3
Rotmensch HH, Belhassen B, Swanson BN, et al. Steady-state serum amiodarone concentrations: relationships with antiarrhythmic efficacy and toxicity. Ann Intern Med. 1984;101(4):462-469. 10.7326/0003-4819-101-4-462
Ingram DV, Jaggarao NS, Chamberlain DA. Ocular changes resulting from therapy with amiodarone. Br J Ophthalmol. 1982;66(10):676-679. 10.1136/bjo.66.10.676
Orr CF, Ahlskog JE. Frequency, characteristics, and risk factors for amiodarone neurotoxicity. Arch Neurol. 2009;66(7):865-869. 10.1001/archneurol.2009.96
Colunga Biancatelli RML, Congedo V, Calvosa L, Ciacciarelli M, Polidoro A, Iuliano L. Adverse reactions of Amiodarone. J Geriatr Cardiol. 2019;16(7):552-566.
Ozbakis-Dengiz G, Bakirci A. Anticonvulsant and hypnotic effects of amiodarone. J Zhejiang Univ Sci B. 2009;10(4):317-322. 10.1631/jzus.B0820316
Arbusow V, Strupp M, Brandt T. Amiodarone-induced severe prolonged head-positional vertigo and vomiting. Neurology. 1998;51(3):917. 10.1212/WNL.51.3.917
van Vliet EA, Aronica E, Gorter JA. Blood-brain barrier dysfunction, seizures and epilepsy. Semin Cell Dev Biol. 2015;38:26-34. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1084952114002973
Marchi N, Granata T, Ghosh C, Janigro D. Blood-brain barrier dysfunction and epilepsy: pathophysiologic role and therapeutic approaches. Epilepsia. 2012;53(11):1877-1886. 10.1111/j.1528-1167.2012.03637.x
Read MI, McCann DM, Millen RN, Harrison JC, Kerr DS, Sammut IA. Progressive development of cardiomyopathy following altered autonomic activity in status epilepticus. Am J Physiol Circ Physiol. 2015;309(9):H1554-H1564. 10.1152/ajpheart.00256.2015
Mezni A, Aoua H, Khazri O, Limam F, Aouani E. Lithium induced oxidative damage and inflammation in the rat’s heart: protective effect of grape seed and skin extract. Biomed Pharmacother. 2017;95:1103-1111. Available from https://linkinghub.elsevier.com/retrieve/pii/S0753332217324757
Auzmendi J, Buchholz B, Salguero J, et al. Pilocarpine-induced status epilepticus is associated with P-glycoprotein induction in cardiomyocytes. Electrocardiographic changes, and sudden death. Pharmaceuticals. 2018;11(1):21. Available from: http://www.mdpi.com/1424-8247/11/1/21
Kodama I, Kamiya K, Toyama J. Amiodarone: ionic and cellular mechanisms of action of the most promising class III agent. Am J Cardiol. 1999;84(9):20-28. Available from https://linkinghub.elsevier.com/retrieve/pii/S0002914999006980
Drvota V, Häggblad J, Blange I, Magnusson Y, Sylvén S. The effect of amiodarone on the β-adrenergic receptor is due to a downregulation of receptor protein and not to a receptor-ligand interaction. Biochem Biophys Res Commun. 1999;255(2):515-520. Available from https://linkinghub.elsevier.com/retrieve/pii/S0006291X98901383
Konopelski P, Ufnal M. Electrocardiography in rats: a comparison to human. Physiol Res. 2016;30:717-725. Available from http://www.biomed.cas.cz/physiolres/pdf/65/65_717.pdf
Ide T, Tsutsui H, Kinugawa S, Utsumi H, Takeshita A. Amiodarone protects cardiac myocytes against oxidative injury by its free radical scavenging action. Circulation. 1999;100(7):690-692. 10.1161/01.CIR.100.7.690
Shimizu M, Kagawa A, Takano T, Masai H, Miwa Y. Neurogenic stunned myocardium associated with status epileptics and postictal catecholamine surge. Intern Med. 2008;47(4):269-273. Available from http://joi.jlc.jst.go.jp/JST.JSTAGE/internalmedicine/47.0499?from=CrossRef
Traupe T, Keller M, Fojtu E, et al. Antioxidant activity and sex differences of acute vascular effects of amiodarone in advanced atherosclerosis. J Cardiovasc Pharmacol. 2007;50(5):578-584. Available from http://journals.lww.com/00005344-200711000-00016
Polat B, Cadirci E, Halici Z, et al. The protective effect of amiodarone in lung tissue of cecal ligation and puncture-induced septic rats: a perspective from inflammatory cytokine release and oxidative stress. Naunyn Schmiedebergs Arch Pharmacol. 2013;386(7):635-643. 10.1007/s00210-013-0862-3
Ito H, Ono K, Nishio R, Sasayama S, Matsumori A. amiodarone inhibits interleukin 6 production and attenuates myocardial injury induced by viral myocarditis in mice. Cytokine. 2002;17(4):197-202. Available from https://linkinghub.elsevier.com/retrieve/pii/S1043466601909962
Bodin K, Bretillon L, Aden Y, et al. Antiepileptic drugs increase plasma levels of 4β-hydroxycholesterolin humans. J Biol Chem. 2001;276(42):38685-38689. Available from https://linkinghub.elsevier.com/retrieve/pii/S0021925820741244
Peternel S, Pilipović K, Župan G. Seizure susceptibility and the brain regional sensitivity to oxidative stress in male and female rats in the lithium-pilocarpine model of temporal lobe epilepsy. Prog Neuro-Psychopharmacology Biol Psychiatry. 2009;33(3):456-462. Available from https://linkinghub.elsevier.com/retrieve/pii/S0278584609000128
Eslami SM, Moradi MM, Ghasemi M, Dehpour AR. Anticonvulsive effects of licofelone on status epilepticus induced by lithium-pilocarpine in wistar rats: a role for inducible nitric oxide synthase. J Epilepsy Res. 2016;6(2):51-58. 10.14581/jer.16011
Read MI, Andreianova AA, Harrison JC, Goulton CS, Sammut IA, Kerr DS. Cardiac electrographic and morphological changes following status epilepticus: effect of clonidine. Seizure. 2014;23(1):55-61. Available from https://linkinghub.elsevier.com/retrieve/pii/S1059131113002720
Mitchell GF, Jeron A, Koren G. Measurement of heart rate and Q-T interval in the conscious mouse. Am J Physiol Circ Physiol. 1998;274(3):H747-H751. 10.1152/ajpheart.1998.274.3.H747